What they were paid
Candel Therapeutics Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $42,500 | $0 | $60,546 | $0 | $103,046 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Candel Therapeutics, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191506, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Candel Therapeutics pays directors a $35,000 cash retainer.
Committees
FY2025 · as the proxy prints themAudit (Chair)
The rest of the Candel Therapeutics board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Christopher Martell | Independent Director | $114,546 |
| Edward J. Benz Jr., M.D | Independent Director | $103,546 |
| Gary J. Nabel, M.D., Ph.D | Independent Director | $99,546 |
| Joseph C. Papa, R.Ph., M.B.A | Independent Director | $101,810 |
| Maha Radhakrishnan, M.D | Independent Director | $158,346 |
| Nicoletta Loggia, Ph.D., R.Ph | Independent Director | $107,019 |
| Paul B. Manning | Independent Director | $130,546 |
| Paul Peter Tak, M.D., Ph.D., FMedSci | Director | $0 |
The full Candel Therapeutics compensation record
free company briefThis page is one director within Candel Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat